Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6600 Dumbarton Circle FREMONT CA 94555 |
Tel: | N/A |
Website: | https://www.personalis.com |
IR: | See website |
Key People | ||
Christopher M. Hall President, Chief Executive Officer, Director | Aaron Tachibana Chief Financial Officer, Chief Operating Officer, Senior Vice President | Richard Chen Executive Vice President - Research and Development, Chief Medical Officer | Stephen Moore Vice President, General Counsel, Corporate Secretary |
Business Overview |
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company's advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company's tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies. |
Financial Overview |
For the fiscal year ended 31 December 2023, Personalis Inc revenues increased 13% to $73.5M. Net loss decreased 4% to $108.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling, general, and administrative decrease of 18% to $42.3M (expense), Stock-based Compensation in SGA decrease of 39% to $7.4M (expense). |
Employees: | 223 as of Jan 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $73.48M as of Dec 31, 2023 |
EBITDA (TTM): | -$84.94M as of Dec 31, 2023 |
Net annual income (TTM): | -$108.30M as of Dec 31, 2023 |
Free cash flow (TTM): | -$67.17M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 50,503,889 as of Feb 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |